The important announcements for Hong Kong stocks yesterday are as follows:

Financial data

$SD GOLD (01787.HK)$: The net profit for the first quarter is expected to be 650 million yuan to 750 million yuan, an increase of 48.11% to 70.90% over the previous year.

Shandong Gold issued an announcement. According to preliminary estimates, net profit attributable to owners of the parent company is expected to be RMB 650 million to RMB 750 million in the first quarter of 2024, an increase of RMB 211 million to RMB 311 million compared with the same period last year, and an increase of 48.11% to 70.90% over the previous year.

$Fast Retailing (06288.HK)$: Announcement of interim results for the six months ended February 29, 2024, with revenue of approximately 1598.999 billion yen, up 9% year on year; net profit of 19.912 billion yen, up 27.7% year on year.

$SMOORE INTL (06969.HK)$: Profit after tax for the first quarter was about 339.5 million yuan, an increase of 12.8% over the previous year.

$CCT FORTIS (00138.HK)$: Announced results for the year ended 31 December 2023, achieving revenue of HK$765 million, a year-on-year decrease of 5.79%; net loss of HK$577 million, an increase of 24.09% year-on-year

Operational data

$TRADEGO (08017.HK)$: In March, 3 new institutional customers were added; 811,700 registered users, up 5.7% year on year; 101,800 new subscribers, up 3.4% year on year.

$KONG SUN HOLD (00295.HK)$: The cumulative total power generation for the first 3 months was about 70,400 megawatt-hours, a year-on-year decrease of 12.94%.

Company news

$XINJI SHAXI (03603.HK)$: 14.16% of the company's shares held by the controlling shareholder were forcibly sold, and trading resumed today.

$GANFENGLITHIUM (01772.HK)$: It is intended to provide financial support of no more than 350 million yuan to Shenzhen Luyuan through Shenzhen China Airlines.

$CARSGEN-B (02171.HK)$: An oral report on the CT041 trial data update at the 2024 ASCO Annual Meeting.

$BIOCYTOGEN-B (02315.HK)$: It is expected to approach break-even in 2024, and no more than HK$10 million will be made for further share purchases.

$XUANWU CLOUD (02392.HK)$: Stock prices have changed, and the Group's business operations have remained normal.

$CHINA FEIHE (06186.HK)$: Affiliated to Heilongjiang Feihe, subscribed to 500 million yuan of financial management products sold by China CITIC Bank.

Buyback News

$TENCENT (00700.HK)$: Approximately HK$1 billion was spent to repurchase 3.18 million shares at a repurchase price of HK$311.2-3 16.6.

$MEITUAN-W (03690.HK)$: HK$400 million was spent to repurchase 3.850,800 shares at a repurchase price of HK$100.60-105.40.

$HSBC HOLDINGS (00005.HK)$: A repurchase of 4,518 million shares was spent at HK$291 million, at a repurchase price of HK$63.95-64.9.

$CK ASSET (01113.HK)$: A repurchase of 1,529,500 shares was spent at HK$49,1664 million, at a repurchase price of HK$31.75-32.35.

$DONGFENG GROUP (00489.HK)$: An amount of HK$24.65 million was spent to repurchase 8.52 million shares at a repurchase price of HK$2.88-2.92.

$TUHU-W (09690.HK)$: A repurchase of 1,135,000 shares was spent at HK$2016 million, at a repurchase price of HK$17.4-17.84.

$KUAISHOU-W (01024.HK)$: Spend HK$1997 million to repurchase 405,000 shares at a repurchase price of HK$48.55-49.95.

$CHINASOFT INT'L (00354.HK)$: Spend HK$19.26 million to repurchase 4 million shares at a repurchase price of HK$4.75-4.86.

$WUXI BIO (02269.HK)$: A repurchase of 1,415,000 shares was spent at HK$19.02 million, with a repurchase price of HK$13.98-14.16.

$3SBIO (01530.HK)$: Spend HK$16.7497 million to repurchase 2.805 million shares at a repurchase price of HK$5.92-6.04.

editor/tolk